Beksac M - Search Results

1

Determination of the Apoptotic Effect and Molecular Docking of Benzamide Derivative XT5 in K562 Cells.

Ozkan T, Hekmatshoar Y, Ertan-Bolelli T, Hidayat AN, Beksac M, Aki-Yalcin E, Yalcin I, Sunguroglu A. Ozkan T, et al. Among authors: beksac m. Anticancer Agents Med Chem. 2018;18(11):1521-1530. doi: 10.2174/1871520618666171229222534. Anticancer Agents Med Chem. 2018. PMID: 29298654

2

Insight into human protease activated receptor-1 as anticancer target by molecular modelling.

Hidayat AN, Aki-Yalcin E, Beksac M, Tian E, Usmani SZ, Ertan-Bolelli T, Yalcin I. Hidayat AN, et al. Among authors: beksac m. SAR QSAR Environ Res. 2015;26(10):795-807. doi: 10.1080/1062936X.2015.1095799. Epub 2015 Oct 26. SAR QSAR Environ Res. 2015. PMID: 26501801

3

A rapid drug sensitivity assay for neoplasmatic cells.

Beksac M, Kansu E, Kars A, Ibrahimoglu Z, Firat D. Beksac M, et al. Med Oncol Tumor Pharmacother. 1988;5(4):253-7. doi: 10.1007/BF03003193. Med Oncol Tumor Pharmacother. 1988. PMID: 2848162

4

Circulating CD44 and intercellular adhesion molecule-1 levels in low grade non-hodgkin lymphoma and B-cell chronic lymphocytic leukemia patients during interferon-alpha-2a treatment.

Beksaç M, Arat M, Akan H, Koç H, Ilhan O, Ozcan M. Beksaç M, et al. Cancer. 2000 Oct 1;89(7):1474-81. Cancer. 2000. PMID: 11013360 Clinical Trial.

5

Flow cytometric evaluation of cell cycle regulators (cyclins and cyclin-dependent kinase inhibitors) expressed on bone marrow cells in patients with chronic myeloid leukemia and multiple myeloma.

Toprak SK, Dalva K, Cakar MK, Kurşun N, Beksaç M. Toprak SK, et al. Among authors: beksac m. Turk J Haematol. 2012 Mar;29(1):17-27. doi: 10.5505/tjh.2012.33602. Epub 2011 Apr 28. Turk J Haematol. 2012. PMID: 24744619 Free PMC article.

6

The safety of bortezomib for the treatment of multiple myeloma.

Cengiz Seval G, Beksac M. Cengiz Seval G, et al. Among authors: beksac m. Expert Opin Drug Saf. 2018 Sep;17(9):953-962. doi: 10.1080/14740338.2018.1513487. Epub 2018 Aug 30. Expert Opin Drug Saf. 2018. PMID: 30118610 Review.

7

Expression of IFITM1 in chronic myeloid leukemia patients.

Akyerli CB, Beksac M, Holko M, Frevel M, Dalva K, Ozbek U, Soydan E, Ozcan M, Ozet G, Ilhan O, Gürman G, Akan H, Williams BR, Ozçelik T. Akyerli CB, et al. Among authors: beksac m. Leuk Res. 2005 Mar;29(3):283-6. doi: 10.1016/j.leukres.2004.07.007. Leuk Res. 2005. PMID: 15661263 Free article.

8

Allogeneic Transplantation in Chronic Myeloid Leukemia and the Effect of Tyrosine Kinase Inhibitors on Survival: A Quasi-Experimental Study.

Özen M, Üstün C, Öztürk B, Topçuoğlu P, Arat M, Gündüz M, Atilla E, Bolat G, Arslan Ö, Demirer T, Akan H, İlhan O, Beksaç M, Gürman G, Özcan M. Özen M, et al. Among authors: beksac m. Turk J Haematol. 2017 Mar 1;34(1):16-26. doi: 10.4274/tjh.2015.0346. Epub 2016 Apr 18. Turk J Haematol. 2017. PMID: 27094579 Free PMC article.

9

Hepatitis B Reactivation Rate and Fate Among Multiple Myeloma Patients Receiving Regimens Containing Lenalidomide and/or Bortezomib.

Ataca Atilla P, Yalçıner M, Atilla E, İdilman R, Beksaç M. Ataca Atilla P, et al. Among authors: beksac m. Turk J Haematol. 2019 Nov 18;36(4):266-273. doi: 10.4274/tjh.galenos.2019.2019.0103. Epub 2019 Aug 1. Turk J Haematol. 2019. PMID: 31368290 Free PMC article.

10

Use of high-dose chemotherapy plus granulocyte colony-stimulating factor for the salvage of refractory or resistant-relapse lymphoma patients without stem cell support.

Koç H, Arslan O, Gürman G, Akan H, Ozcan M, Ilhan O, Aydoğdu I, Arat M, Beksaç M, Konuk N, Uysal A. Koç H, et al. Among authors: beksac m. Acta Haematol. 1997;98(3):136-9. doi: 10.1159/000203607. Acta Haematol. 1997. PMID: 9352743 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

458 results

Search Page